Aurélie Pétain

431 total citations
18 papers, 320 citations indexed

About

Aurélie Pétain is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aurélie Pétain has authored 18 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aurélie Pétain's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Aurélie Pétain is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Aurélie Pétain collaborates with scholars based in France, China and Spain. Aurélie Pétain's co-authors include Étienne Chatelut, Gilles Vassal, Catherine Delbaldo, Birgit Geoerger, Sophie Séronie-Vivien, A. Lecesne, Michel Barrois, Laurent Nguyen, Bénédicte Neven and Angélo Paci and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Aurélie Pétain

18 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aurélie Pétain France 8 134 126 100 68 43 18 320
Yoichiro Ogama Japan 10 72 0.5× 110 0.9× 190 1.9× 34 0.5× 18 0.4× 16 609
Matthew Clement United States 5 83 0.6× 94 0.7× 155 1.6× 144 2.1× 8 0.2× 5 467
Miguel Franquiz United States 7 197 1.5× 59 0.5× 76 0.8× 66 1.0× 20 0.5× 11 279
Britt Sundman‐Engberg Sweden 12 119 0.9× 184 1.5× 161 1.6× 32 0.5× 31 0.7× 20 346
Renate Schottmann Germany 14 100 0.7× 94 0.7× 186 1.9× 30 0.4× 163 3.8× 24 460
Manuel Litchman United States 10 140 1.0× 435 3.5× 189 1.9× 50 0.7× 147 3.4× 11 544
Aksana Vasilyeva United States 8 29 0.2× 123 1.0× 135 1.4× 29 0.4× 22 0.5× 13 302
Guowei Dai China 9 156 1.2× 68 0.5× 268 2.7× 55 0.8× 5 0.1× 18 451
Andrew D. Louie United States 5 119 0.9× 139 1.1× 240 2.4× 15 0.2× 49 1.1× 7 544
Sung‐Soo Yoon South Korea 12 133 1.0× 96 0.8× 85 0.8× 67 1.0× 12 0.3× 42 364

Countries citing papers authored by Aurélie Pétain

Since Specialization
Citations

This map shows the geographic impact of Aurélie Pétain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Pétain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Pétain more than expected).

Fields of papers citing papers by Aurélie Pétain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Pétain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Pétain. The network helps show where Aurélie Pétain may publish in the future.

Co-authorship network of co-authors of Aurélie Pétain

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Pétain. A scholar is included among the top collaborators of Aurélie Pétain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Pétain. Aurélie Pétain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gomez‐Roca, Carlos, Stéphane Champiat, Philippe A. Cassier, et al.. (2024). Abstract CT181: First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research. 84(7_Supplement). CT181–CT181. 4 indexed citations
2.
Melero, Ignacio, Carlos Gomez‐Roca, Pierre Ferré, et al.. (2020). 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody. SHILAP Revista de lepidopterología. A193.2–A194. 5 indexed citations
3.
Pétain, Aurélie, Dafang Zhong, Xiaoyan Chen, et al.. (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer Chemotherapy and Pharmacology. 84(2). 373–382. 4 indexed citations
4.
5.
Léary, Alexandra, Christophe Le Tourneau, Andréa Varga, et al.. (2018). Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. Investigational New Drugs. 37(4). 693–701. 11 indexed citations
6.
Schmitt, Antonin, et al.. (2018). Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials. British Journal of Clinical Pharmacology. 84(5). 900–910. 2 indexed citations
7.
Tierny, Dominique, François Serres, Emmanuel Bouchaert, et al.. (2015). Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clinical Cancer Research. 21(23). 5314–5323. 19 indexed citations
8.
9.
Gaziev, Javid, Antonella Isgrò, Alessia Francesca Mozzi, et al.. (2014). New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. Pediatric Blood & Cancer. 62(4). 680–686. 14 indexed citations
10.
Delord, Jean‐Pierre, J.M. Tourani, Florence Lefresne, et al.. (2013). Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours. Cancer Chemotherapy and Pharmacology. 71(3). 647–656. 2 indexed citations
11.
Isambert, Nicolás, Jean Pierre Delord, Jean Marc Tourani, et al.. (2013). How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. British Journal of Clinical Pharmacology. 77(3). 498–508. 8 indexed citations
12.
Paci, Angélo, Gilles Vassal, Despina Moshous, et al.. (2012). Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children. Therapeutic Drug Monitoring. 34(2). 198–208. 65 indexed citations
13.
Calvo, Emiliano, Jan B. Vermorken, Sandrine Hiret, et al.. (2012). Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemotherapy and Pharmacology. 69(6). 1467–1475. 3 indexed citations
14.
15.
Pétain, Aurélie & Étienne Chatelut. (2008). [Anticancer drug dose individualisation: from body surface area to physiology].. PubMed. 95(10). 895–901. 4 indexed citations
16.
Pétain, Aurélie, Étienne Chatelut, Catherine Delbaldo, et al.. (2008). Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults. Clinical Cancer Research. 14(21). 7102–7109. 118 indexed citations
17.
Chatelut, Étienne, Aurélie Pétain, Catherine Delbaldo, et al.. (2008). Population pharmacokinetics of imatinib in children and adults. Journal of Clinical Oncology. 26(15_suppl). 2526–2526. 2 indexed citations
18.
Rouits, Elisabeth, Virginie Charasson, Aurélie Pétain, et al.. (2008). Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British Journal of Cancer. 99(8). 1239–1245. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoichiro Ogama Breakdown of academic impact, for papers by Matthew Clement Breakdown of academic impact, for papers by Miguel Franquiz Breakdown of academic impact, for papers by Britt Sundman‐Engberg Breakdown of academic impact, for papers by Renate Schottmann Breakdown of academic impact, for papers by Manuel Litchman Breakdown of academic impact, for papers by Aksana Vasilyeva Breakdown of academic impact, for papers by Guowei Dai Breakdown of academic impact, for papers by Andrew D. Louie Breakdown of academic impact, for papers by Sung‐Soo Yoon
Rankless by CCL
2026